John Simboli

knowledgeable folks like institutional investors hear you talk about the company, what do they understand correctly from your viewpoint, you know, accurately?

What is the misunderstanding?

Is there a common misunderstanding?

Then how do you get it back on track?

Is there anything in particular that you are eager to investigate that you'd like to talk about?

I mean, I guess we're all talking about AI, but...

Thanks for speaking with me today, David.

Speaking with David Southwell about leadership in biopharma was notable for his plain language and appreciation of both challenges and opportunities.

As David said with a good natured chuckle, any biotech who honestly says they sleep well at night is probably naive.

My guess is that part of David's eyes wide open view comes from his experience in capital markets.

He's seen firsthand how challenging it can be to marry scientific innovation with business acumen in a setting where uncertainty is the coin of the realm.

In David's words, science happens.

David said the best way to deal with uncertainty is to be transparent about the risks.

He added, to the extent that you're relatively humble and transparent, it helps.

While transparency is a big help, successful leadership requires making good decisions.

In David's words, you better be right.

You better be operating in a way that will keep your employees and keep a culture and keep the plates spinning.

I'm John Simboli.

You're listening to BioBoss.

That's the voice of Stacey Lindborg, CEO of Immunon, headquartered in Lawrenceville, New Jersey.